Hikma conducted a pharmacodynamic study versus originator insuring the high-quality of Cloplav in inhibiting platelet aggregation Hikma markets Cloplav in Jordan and Iraq.
3 March 2010
Product, Press Release
3 March 2010
Product, Press Release
Hikma conducted a pharmacodynamic study versus originator insuring the high-quality of Cloplav in inhibiting platelet aggregation Hikma markets Cloplav in Jordan and Iraq.